To the Editor:
Neoantigen-specific tumor-infiltrating T lymphocytes are immune effector cells for cancer elimination and are the primary focus of current cancer immunotherapies1, 2, 3, 4. We previously published a novel method to assemble T cell receptor (TCR) complementarity-determining region 3 (CDR3) sequences using paired-end tumor RNA–seq data5. Extending this approach,…